Esomeprazole

Major

Esomeprazole Acalabrutinib Calquence Reduced acalabrutinib exposure Details Esomeprazole Belumosudil Rezurock Reduced belumosudil exposure Details Esomeprazole Atezolizumab Injection Tecentriq Impaired efficacy of atezolizumab Details Esomeprazole Bosutinib Bosulif Reduced bosutinib exposure Details Esomeprazole Capecitabine Xeloda Reduction in capecitabine efficacy Details Esomeprazole Cefuroxime Ceftin® Decreased cefuroxime axetil exposure Details Esomeprazole Clopidogrel Plavix Reduced clopidogrel active metabolite exposure and reduced antiplatelet activity Details Esomeprazole Dacomitinib Vizimpro Reduced dacomitinib exposure Details Esomeprazole Dasatinib Phyrago Reduced dasatinib exposure Details Esomeprazole Digoxin Cardoxin® Increased digoxin exposure Details Esomeprazole Erlotinib Tarceva Reduced erlotinib exposure Details Esomeprazole Alfentanil Increased ALfentanil exposure and an increased risk of respiratory depression Details Esomeprazole Amphetamine Dexedrine Increased exposure to amphetamine Details Esomeprazole Apalutamide Erleada Reduced CYP2C19 substrate exposure Details Esomeprazole Atazanavir Reyataz Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Esomeprazole Atezolizumab Tecentriq Impaired efficacy of atezolizumab Details Esomeprazole Belzutifan Welireg Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Esomeprazole Benzphetamine Increased exposure to amphetamine Details Esomeprazole Cannabidiol Epidiolex Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Esomeprazole Carbamazepine Carbatrol Reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 substrate Details Esomeprazole Cefuroxime Axetil Decreased cefuroxime axetil exposure Details Esomeprazole Cilostazol Pletal® Increased cilostazol exposure Details Esomeprazole Citalopram Celexa Increased citalopram exposure and an increased risk of QT interval prolongation Details Esomeprazole Defactinib Reduced defactinib exposure and an reduced efficacy of defactinib Details Esomeprazole Dextroamphetamine Dexedrine Increased exposure to amphetamine Details Esomeprazole Escitalopram Lexapro Increased escitalopram exposure Details Esomeprazole Eslicarbazepine Acetate Aptiom Increased exposure of CYP2C19 substrates Details Esomeprazole Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Esomeprazole Gefitinib Iressa Decreased exposure of gefitinib Details Esomeprazole Haloperidol Increased haloperidol exposure and an increased risk of haloperidol-related adverse events, including QTc interval prolongation Details Esomeprazole Infigratinib Truseltiq Decreased infigratinib plasma concentrations Details Esomeprazole Ketoconazole Extina Reduced ketoconazole exposure and reduced efficacy of ketoconazole Details Esomeprazole Ledipasvir Decreased ledipasvir exposure and loss of efficacy Details Esomeprazole Lemborexant Dayvigo Increased lemborexant exposure and an increased risk of lemborexant-related adverse reactions. Details Esomeprazole Levoketoconazole Recorlev Reduced levoketoconazole exposure Details Esomeprazole Lisdexamfetamine Arynta Increased exposure to amphetamine Details Esomeprazole Lomitapide Increased lomitapide exposure Details Esomeprazole Lonafarnib Zokinvy Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse effects Details Esomeprazole Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Esomeprazole Mavacamten Camzyos Increased mavacamten exposure, an increased risk of mavacamten-related adverse reactions, reduced esomeprazole exposure and reduce... Details